Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
description
Transcript of Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 1: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/1.jpg)
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 2: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/2.jpg)
Disclosures
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 3: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/3.jpg)
Study Rationale
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 4: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/4.jpg)
Study 303: Study Schema
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 5: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/5.jpg)
Patient Characteristics
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 6: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/6.jpg)
Primary Endpoint:<br />Kaplan-Meier Estimate of PFS
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 7: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/7.jpg)
PFS by Previous VEGF-Targeted Therapy
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 8: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/8.jpg)
PFS Subgroup Analyses
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 9: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/9.jpg)
Response Rates
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 10: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/10.jpg)
Best Tumor Response
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 11: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/11.jpg)
Overall Survival, ITT population
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 12: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/12.jpg)
Study Medication Exposure
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 13: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/13.jpg)
Treatment-emergent Adverse Events (TEAEs)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 14: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/14.jpg)
Most Frequent Treatment-related Adverse Events (> 20%)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 15: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/15.jpg)
TEAEs of Special Interest
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 16: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/16.jpg)
Conclusions
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
![Page 17: Presented By Martin Schlumberger at 2014 ASCO Annual Meeting](https://reader035.fdocuments.us/reader035/viewer/2022062501/56816687550346895dda3641/html5/thumbnails/17.jpg)
Slide 17
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting